| 赵艳敏,于小杰,王娜,牛春密.莫西沙星联合信必可都保对AECOPD疗效及免疫炎症反应的影响.[J].中南医学科学杂志.,2022,(6):902-905. |
| 莫西沙星联合信必可都保对AECOPD疗效及免疫炎症反应的影响 |
| Effect of moxifloxacin combined with symbicort turbuhaler on the efficacy and immune inflammatory response of AECOPD |
| 投稿时间：2021-12-08 修订日期：2022-06-27 |
| DOI：10.15972/j.cnki.43-1509/r.2022.06.030 |
| 中文关键词: 莫西沙星 信必可都保 慢性阻塞性肺疾病 免疫球蛋白 环氧化酶-2 前列腺素E2 [ |
| 英文关键词:moxifloxacin symbicort turbuhaler chronic obstructive pulmonary disease immunoglobulin cyclooxygenase-2 prostaglandin E2 |
| 基金项目:秦皇岛市重点研发计划科技支撑项目(201902A092) 作者简介:赵艳敏,硕士,主管药师,研究方向为药剂相关研究,E-mail为weizhishu1986@126.com。通信作者王娜,博士,主任药师,研究方向为药理学相关研究,E-mail为wangncqhd@163.com。 |
|
| 摘要点击次数: 468 |
| 全文下载次数: 493 |
| 中文摘要: |
| 目的探讨莫西沙星联合信必可都保对慢性阻塞性肺疾病急性加重期(AECOPD)疗效及免疫炎症反应的影响。 方法AECOPD患者130例按用药情况分为莫西沙星组42例,信必可都保组41例和联合组47例。比较各组治疗前后临床疗效、肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FEV1/FVC],以及二氧化碳分压(PaCO2)、氧分压(PaO2)、免疫球蛋白IgG、IgA、IgM、血清环氧化酶-2(COX-2)、前列腺素E2(PGE2)和不良反应情况。 结果联合组总有效率高于莫西沙星组和信必可都保组(P＜0.05)。与治疗前比较,各组治疗后FVC、FEV1、FEV1/FVC、PaO2、IgG、IgA、IgM升高,PaCO2、COX-2、PGE2降低(P＜0.05),且联合组改善更为明显(P＜0.05)。各组不良反应总发生率差异无显著性(P＞0.05)。 结论莫西沙星联合信必可都保治疗AECOPD可提高临床疗效,增强患者免疫功能,值得临床推广。 |
| 英文摘要: |
| To investigate the effect of moxifloxacin combined with symbicort turbuhaler on the curative effect and immune inflammatory reaction of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods130 patients with AECOPD were divided into moxifloxacin group (42 cases), symbicort turbuhaler group (41 cases) and combination group (47 cases). The clinical efficacy, pulmonary function indexes (forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), FEV1/FVC), partial pressure of carbon dioxide (PaCO2), partial pressure of oxygen (PaO2), immunoglobulin IgG, IgA, IgM, serum cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2) and adverse reactions were compared before and after treatment in each group. ResultsThe total effective rate of the combined group was higher than moxifloxacin group and symbicort turbuhaler group (P＜0.05). Compared with that before treatment, FVC, FEV1, FEV1/FVC, PaO2, IgG, IgA and IgM increased, PaCO2, COX-2 and PGE2 were decreased in each group after treatment (P＜0.05), and the improvement was more obvious in the combined group (P＜0.05). There was no significant difference in the total incidence of adverse reactions among the groups (P＞0.05). ConclusionMoxifloxacin combined with symbicort turbuhaler in the treatment of AECOPD can improve the clinical efficacy and enhance the immune function of patients, which is worthy of clinical promotion. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|